New paper led by Shai Shimony and our #BPDCN Center Dana-Farber: Organ Involvement in Adults with BPDCN is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival ashpublications.org/bloodadvances/…

I have the pleasure and privilege to dive into #BPDCN under the amazing mentorship of the one and only Andy Lane Dana-Farber News. 🌞=>TET2=>Skin involvement| RAS=> Systemic involvement | Overt BM (>5%)=>⬇️OS.

IFYKYK … two of the true OGs of #BMT catching the eclipse and looking good doing it ⁦⁦Dana-Farber⁩ ⁦Rizwan Romee⁩ ⁦Mahasweta Gooptu⁩ ⁦Corey Cutler⁩

New research from Dana-Farber’s Greg Abel, MD and Andrew Hantel, MD provides a first look at oncologists viewpoints about the ethical implications of AI in cancer care

dana-farber.org/newsroom/news-…

I had the privilege to serve as a guest editor with Dr. Stone for a special issue of #AMLsm management in Acta Haematologica, in memoriam of Prof. Ben-Bassat. The issue cover 9 practical topics. Thanks to our wonderful contributors⬇️.
karger.com/aha/issue/147/2 Research | Karger

The impact of molecular ontogeny in AML treated with HMA+VEN is unknown. We found that Secondary ontogeny is selectively responsive to VEN added to HMA and the addition of VEN has no clinical benefit in TP53-mutated AML. rdcu.be/dCCZI Leukemia Journal #amlsm Dana-Farber News

What are the outcomes of patients with #BPDCN and AML treated with tagraxofusp combined with azacitidine & venetoclax?

Andy Lane (@DanaFarber) discusses the findings in a recent interview:

👉 ow.ly/RiGF50QStgy

#RareDisease #HemOnc #Hematology #ESHAL2024 ESH (Haematology)

We recently spoke with Andy Lane (@DanaFarber) at #ESHAL2024 to hear an update on the current treatment landscape for #BPDCN .

Click here to visit our site and watch the interview:

👉 ow.ly/2yka50QNJUh

#RareDisease #HemOnc #Hematology ESH (Haematology)

Update: Cigna Healthcare after a peer to peer review Cigna Healthcare denied my request. It was denied by a family medicine practitioner who has never in their life treated a patient with leukemia. In what world are we living here? Cigna Healthcare is this how you treat your patients? Really? Do better!!

Data from Maximilian Stahl featured in #ESHAL2024 provocative debate between Keith W Pratz MD and #AgnieszkaWierzbowska on whether VEN/AZA or intensive chemo is “best” in an #AML patient who goes to alloHSCT (IMHO, there is no answer: need ITT/ randomized data more focus on disease biology!)

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

Congratulations to Corey Cutler, MD, MPH (Corey Cutler) who has been named President of the American Society for Transplantation and Cell Therapy (@ASTCT). Cutler is the Director of Adult Stem Cell Transplantation Program at Dana-Farber.

Day 2- outcomes in molecularly-defined sAML with HMA + VEN compared to intensive chemo Shai Shimony Maximilian Stahl

nature.com/articles/s4137…

Tri-ing to decipher trisomy AML
onlinelibrary.wiley.com/doi/10.1111/bj…
#leusm Shai Shimony

👉👉 Excited to share that our trial of ponatinib (as LCK inhibitor) + VEN + mini-CVD for R/R T-ALL is now open
👉Joint collaboration MDACC and St Jude
Jun Yang Jiyang Yu showed 40% T-ALL overexpress LCK and sensitive to ponatinib/dasatinib (Notably, none had ABL fusion) 1/2

Dr. Robert Soiffer, our inspirational leader Dana-Farber, giving the honorific CIBMTR Mortimer Bortin lecture at #Tandem24 . So well deserved.

The kind of mentor and colleague you can only dream of having!! So proud 😃

Congrats Shai Shimony Maximilian Stahl !

TAG-AZA-VEN has encouraging activity in older patients with previously untreated, adverse-risk AML, including with somatic TP53 mutations. ow.ly/LP9f50QzfoE #clinicaltrialsandobservations #myeloidneoplasia

My lab is still has an open clinical research coordinator position. Apply if interested! careers.dana-farber.org/job/clinical-r…